TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03318861

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KITE-585
Description: A single infusion of KITE-585 autologous anti-BCMA CAR T cells

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KITE-585
Description: A single infusion of KITE-585 autologous anti-BCMA CAR T cells

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KITE-585
Description: A single infusion of KITE-585 autologous anti-BCMA CAR T cells

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KITE-585
Description: A single infusion of KITE-585 autologous anti-BCMA CAR T cells

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KITE-585
Description: A single infusion of KITE-585 autologous anti-BCMA CAR T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study: NCT02995772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Comparison of efficacy with chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOB
Description: Comparison of efficacy with chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FAC
Description: Comparison of efficacy with hormonal therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors (Femara)
Description: Comparison of efficacy with chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors (Aromasin)
Description: Comparison of efficacy with chemotherapy
Study: NCT03318861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study: NCT02112383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior group therapy
Description: For participants in the group intervention condition, the modules from a self-help treatment for procrastination will be delivered at four consecutive three-hour sessions at the Student Health Centre at Karolinska Institutet, with approximately two modules given at each session. The sessions will be spaced two weeks apart, during which participants are instructed to complete assignments related to the modules that were in focus of the previous session, e.g., goal-setting, time management, and behavioral experiments, which they are advised to present and discuss with the other participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy
Description: For participants in the Internet-based condition, the modules from a self-help treatment for procrastination will be distributed weekly during the treatment period, with one module given each week, i.e., ten weeks. In comparison to the group condition, participants will not receive a therapist contact or attend any sessions. In addition, the participants are expected to complete both the reading material and the assignments that are included in each module.
Study: NCT03911128

Intervention type: OTHER
Intervention: Observational
Description: Observational study - no intervention
Study: NCT04694274

Intervention type: DEVICE
Intervention: stabilization splint
Description: The device made of a hard acrylic on stone cast of the upper jaw in the centric relation position. It has a thickness of 1.5 mm at the level of the first molar.

Intervention type: PROCEDURE
Intervention: physical therapy
Description: Home-exercise program included exercises for passive and active stretching, joint mobilization, passive extension, and translational movements to the right, left, and forward.

Intervention type: DEVICE
Intervention: placebo splint
Description: The placebo splint was made of thin heat-treatable foil (0.5 mm). The foil was heated and printed over a plaster model of the upper jaw resulting in a very thin film over the occlusal surfaces of all teeth.
Study: NCT03437005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desonide 0.05%
Description: Desonide 0.05% ointment topically twice daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2%
Description: Ketoconazole 2% cream topically twice daily for two weeks
Study: NCT02244866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pergoveris (FSH and LH)
Description: Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alpha (FSH)
Description: Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Study: NCT04020900

Intervention type: OTHER
Intervention: Respiratory management
Description: Data on respiratory management were collected at different time: data regarding the induction period, ventilatory parameters set and measured during a stable period, ventilatory change made during anaesthesia, use of recruitment manoeuvres, data regarding weaning and extubation
Study: NCT00325468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 162
Description: AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
Study: NCT04357574

Intervention type: OTHER
Intervention: Telehealth
Description: patients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
Study: NCT01063400

Intervention type: OTHER
Intervention: Observation
Description: monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
Study: NCT04827511

Intervention type: OTHER
Intervention: Refraction measurement with auto-ref-keratometer Canon
Description: Refractive measurement and vitamin D level dosing

Intervention type: OTHER
Intervention: Refraction measurement with auto-ref-keratometer Canon
Description: Refractive measurement and vitamin D level dosing
Study: NCT04478968

Intervention type: OTHER
Intervention: presence of AVF
Description: Functioning AVF may have cardiotoxic potential
Study: NCT03033823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
Study: NCT00622128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventing Aggressive Behavior in Demented Patients
Description: Preventing Aggressive Behavior in Demented Patients
Study: NCT03662854

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline
Description: Patients will receive 2 mL of Phosphate Buffered Saline separated by 6 weeks (total of 4 mL of Phosphate Buffered Saline)
Study: NCT01780584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral T3 Low dose
Description: Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral T3 high dose
Description: Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
Study: NCT02330861

Intervention type: DEVICE
Group type: OTHER
Intervention: combowire and IVUS
Study: NCT01126177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1a
Description: SNG001, IFN-β1a solution for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (excipients of the SNG001 solution only)
Study: NCT03427879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low flavonoid beverage
Description: A low flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), placebo blueberry powder (2.4%), alkalized cocoa powder (1.6%), and whey protein isolate (0.6%). The beverage will contain approximately 5mg flavonoids per serving.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High flavonoid beverage
Description: A high flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), blueberry powder (2.4%), cocoa powder (1.6%), green tea extract (0.1%) and whey protein isolate (0.6%). The beverage will contain approximately 620 mg flavonoids per serving.
Study: NCT00496041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Registry
Description: A Registry will be used.
Study: NCT03732209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
Study: NCT00562484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Limited Influenza Vaccine
Description: A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT02375607

Intervention type: DEVICE
Group type: OTHER
Intervention: Algometer
Description: Algometer performed patients
Study: NCT01114334

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-Based Medical Management
Description: We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline-Based Medical Management
Description: We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing for Depression
Description: Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
Study: NCT03221816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenavit®
Description: The experimental group received one tablet of Tenavit® daily for a period of 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
Study: NCT01214967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Education
Description: psycho-educational intervention
Study: NCT02464163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panblok
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panblok
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panblok
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panblok
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHA adjuvant
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHA adjuvant
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHA adjuvant
Description: Intramuscular injection
Study: NCT02741661

Intervention type: OTHER
Intervention: No intervention. Observational study
Description: No intervention

Intervention type: OTHER
Intervention: No intervention. Observational study
Description: No intervention
Study: NCT01695174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xifaxan
Study: NCT01149564

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iv ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ibuprofen
Study: NCT04576520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacopuncture therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
Study: NCT00591565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: acamprosate 333mg tab, 3 by mouth 3 times a day
Study: NCT04895657

Intervention type: DRUG
Group type: OTHER
Intervention: Piperacillin/Tazobactam Continuous infusion
Description: Continuous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Piperacillin/Tazobactam Intermittent infusion
Description: Intermittent infusion
Study: NCT04339153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training for Disruptive Behaviours
Description: Critically, PT also involves education about autism during the initial sessions, and thus benefits of PT are inferred to come from the specific training.
Study: NCT04835610

Intervention type: DEVICE
Intervention: pvi
Description: The Plethysmographic Variability Index (PVI) can be measured with both finger and forehead probes. Vasoconstriction may reduce the reliability of PVI measurements in pediatric surgical patients prone to hypothermia. The vascular structure of the forehead area is resistant to changes in vasomotor tonus. The aim of our study is to compare the efficacy of PVI values measured at the finger and forehead areas to predict fluid responsiveness in these patients.

Intervention type: DEVICE
Intervention: pvi
Description: The Plethysmographic Variability Index (PVI) can be measured with both finger and forehead probes. Vasoconstriction may reduce the reliability of PVI measurements in pediatric surgical patients prone to hypothermia. The vascular structure of the forehead area is resistant to changes in vasomotor tonus. The aim of our study is to compare the efficacy of PVI values measured at the finger and forehead areas to predict fluid responsiveness in these patients.
Study: NCT03056638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix monthly for 6 months

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiosurgery (SBRT)
Description: SBRT 8 Gy x 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiosurgery (SBRT)
Description: SBRT 8 Gy x 5
Study: NCT02323542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition intervention with cereal products
Description: acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition intervention with cereal products
Description: acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
Study: NCT02075931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity feedback with group meetings
Description: Physical activity feedback

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention
Study: NCT03732209

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Thinking
Description: Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
Study: NCT01858168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets to be taken on an empty stomach twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets to be taken on an empty stomach twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets to be taken on an empty stomach twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Tablets to be taken on an empty stomach before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Tablets to be taken on an empty stomach before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Tablets to be taken on an empty stomach before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered via IV
Study: NCT03206346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin
Description: Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo, capsules daily for 5 days.
Study: NCT02362490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alpha 2a
Description: in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
Study: NCT03541759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone Hcl 4Mg Tab
Description: Hydal retard 4Mg Tab 2 times after surgery as basic medication. Hydal retard 2.6Mg maximum 2 per 24h when NRS \> 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramide 15mg s.c.
Description: Dipidolor 15mg s.c. 2 times after surgery as basic medication. Dipidolor 7.5mg s.c. maximum 2 per 24h when NRS \> 5.
Study: NCT04551378

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT03586102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein supplementation
Description: To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive \> 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard protein supplementation
Description: Infants assigned to the standard protein supplementation group will receive fortified human milk (\< 4.5 g/kg/day of enteral protein)
Study: NCT04250194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-Guided Biopsy
Description: Images will be generated by a CT scanner to accurately insert a needle into the lung nodule allowing a sample to be removed for testing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation bronchoscopy
Description: A virtual three-dimensional map of the lung will be generated enabling the physician to perform an anatomically precise biopsy
Study: NCT02034747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: oral
Study: NCT01149980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram Hydrobromide
Description: Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram Hydrobromide
Description: Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
Study: NCT02034747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: oral
Study: NCT03775850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EDP1503
Description: 4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EDP1503
Description: 4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EDP1503
Description: 4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg given by intravenous (IV) infusion once every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg given by intravenous (IV) infusion once every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg given by intravenous (IV) infusion once every 3 weeks
Study: NCT06229561

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Feasibility of soft tissue graft after immediate implant placement

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Feasibility of soft tissue graft after immediate implant placement